Search Results - "Ballard, Hatcher J."

Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer by Lee, Yong Gu, Guruprasad, Puneeth, Ghilardi, Guido, Pajarillo, Raymone, Sauter, Christopher Tor, Patel, Ruchi, Ballard, Hatcher J, Hong, Seok Jae, Chun, Inkook, Yang, Nicholas, Amelsberg, Kimberly V, Cummins, Katherine D, Svoboda, Jakub, Gill, Saar, Chong, Elise A, North, Khrystyna, Church, Sarah E, Fraietta, Joseph A, Chang, Wan-Jung, Lacey, Simon F, Lu, Xueqing Maggie, Zhang, Yunlin, Whig, Kanupriya, Schultz, David C, Cherry, Sara, Gerson, James, Schuster, Stephen J, Porazzi, Patrizia, Ruella, Marco

“…Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL);…”
Get more information

Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing by Pajarillo, Raymone, Paruzzo, Luca, Carturan, Alberto, Ugwuanyi, Ositadimma, White, Griffin, Guruprasad, Puneeth, Ballard, Hatcher J, Patel, Ruchi P, Zhang, Yunlin, Lee, Yong Gu, Hong, Seok Jae Albert, Dittami, Gregory M., Ruella, Marco

“…The successful development of CD19-targeted chimeric antigen receptor (CAR) T-cell therapies has led to an exponential increase in the number of patients…”
Get full text

The BTLA–HVEM axis restricts CAR T cell efficacy in cancer by Guruprasad, Puneeth, Carturan, Alberto, Zhang, Yunlin, Cho, Jong Hyun, Kumashie, Kingsley Gideon, Patel, Ruchi P., Kim, Ki-Hyun, Lee, Jong-Seo, Lee, Yoon, Kim, Jong Hoon, Chung, Junho, Joshi, Akshita, Cohen, Ivan, Shestov, Maksim, Ghilardi, Guido, Harris, Jaryse, Pajarillo, Raymone, Angelos, Mathew, Lee, Yong Gu, Liu, Shan, Rodriguez, Jesse, Wang, Michael, Ballard, Hatcher J., Gupta, Aasha, Ugwuanyi, Ositadimma H., Hong, Seok Jae Albert, Bochi-Layec, Audrey C., Sauter, Christopher T., Chen, Linhui, Paruzzo, Luca, Kammerman, Shane, Shestova, Olga, Liu, Dongfang, Vella, Laura A., Schuster, Stephen J., Svoboda, Jakub, Porazzi, Patrizia, Ruella, Marco

“…The efficacy of T cell-based immunotherapies is limited by immunosuppressive pressures in the tumor microenvironment. Here we show a predominant role for the…”
Get full text

Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas by Angelos, Mathew G, Ballard, Hatcher J, Barta, Stefan K

“…Peripheral T-cell lymphomas (PTCLs) are a rare and heterogenous subset of non-Hodgkin lymphoma characterized by an aggressive clinical course. Historically,…”
Get full text

Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting by Nasta, Sunita D., Hughes, Mitchell E., Namoglu, Esin C., Garfall, Alfred, DiFilippo, Heather, Ballard, Hatcher J., Barta, Stefan K., Chong, Elise A., Frey, Noelle V., Gerson, James N., Landsburg, Daniel J., Ruella, Marco, Schuster, Stephen J., Svoboda, Jakub, Weber, Elizabeth, Porter, David L.

“…Chimeric antigen receptor T-cell therapy (CAR T) is a revolutionary adoptive immunotherapy approach in lymphoma; however, substantial resources are necessary…”
Get full text

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma by Ruff, Andrew, Ballard, Hatcher J., Pantel, Austin R., Namoglu, Esin C., Hughes, Mitchell E., Nasta, Sunita D., Chong, Elise A., Bagg, Adam, Ruella, Marco, Farwell, Michael D., Svoboda, Jakub, Sellmyer, Mark A.

“…Purpose 18 F-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is a well-established imaging modality to assess responses in…”
Get full text

Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines by Ghilardi, Guido, Paruzzo, Luca, Svoboda, Jakub, Chong, Elise A., Shestov, Alexander A., Chen, Linhui, Cohen, Ivan J., Gabrielli, Giulia, Nasta, Sunita D., Porazzi, Patrizia, Landsburg, Daniel J., Gerson, James N., Carter, Jordan, Barta, Stefan K., Yelton, Rebecca, Pajarillo, Raymone, Patel, Vrutti, White, Griffin, Ballard, Hatcher J., Weber, Elizabeth, Napier, Ellen, Chong, Emeline R., Fraietta, Joseph A., Garfall, Alfred L., Porter, David L., Milone, Michael C., O’Connor, Roderick, Schuster, Stephen J., Ruella, Marco

“…•Bendamustine lymphodepletion before axicabtagene ciloleucel is effective and associated with reduced toxicity than Flu/Cy.•Bendamustine lymphodepletion…”
Get full text

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma by Merryman, Reid W., Redd, Robert A., Nishihori, Taiga, Chavez, Julio, Nieto, Yago, Darrah, Justin M., Rao, Uttam, Byrne, Michael T., Bond, David A., Maddocks, Kami J., Spinner, Michael A., Advani, Ranjana H., Ballard, Hatcher J., Svoboda, Jakub, Singh, Anurag K., McGuirk, Joseph P., Modi, Dipenkumar, Ramchandren, Radhakrishnan, Romancik, Jason, Cohen, Jonathon B., Frigault, Matthew J., Chen, Yi-Bin, Serritella, Anthony V., Kline, Justine, Ansell, Stephen, Nathan, Sunita, Rahimian, Maryam, Joyce, Robin M., Shah, Mansi, David, Kevin A., Park, Steven, Beaven, Anne W., Habib, Alma, Bachanova, Veronika, Nakhoda, Shazia, Khan, Nadia, Lynch, Ryan C., Smith, Stephen D., Ho, Vincent T., LaCasce, Ann, Armand, Philippe, Herrera, Alex F.

“…Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that…”
Get full text

CD5 deletion enhances the antitumor activity of adoptive T cell therapies by Patel, Ruchi P, Ghilardi, Guido, Zhang, Yunlin, Chiang, Yi-Hao, Xie, Wei, Guruprasad, Puneeth, Kim, Ki Hyun, Chun, Inkook, Angelos, Mathew G, Pajarillo, Raymone, Hong, Seok Jae, Lee, Yong Gu, Shestova, Olga, Shaw, Carolyn, Cohen, Ivan, Gupta, Aasha, Vu, Trang, Qian, Dean, Yang, Steven, Nimmagadda, Aditya, Snook, Adam E, Siciliano, Nicholas, Rotolo, Antonia, Inamdar, Arati, Harris, Jaryse, Ugwuanyi, Ositadimma, Wang, Michael, Carturan, Alberto, Paruzzo, Luca, Chen, Linhui, Ballard, Hatcher J, Blanchard, Tatiana, Xu, Chong, Abdel-Mohsen, Mohamed, Gabunia, Khatuna, Wysocka, Maria, Linette, Gerald P, Carreno, Beatriz, Barrett, David M, Teachey, David T, Posey, Avery D, Powell, Jr, Daniel J, Sauter, C Tor, Pileri, Stefano, Pillai, Vinodh, Scholler, John, Rook, Alain H, Schuster, Stephen J, Barta, Stefan K, Porazzi, Patrizia, Ruella, Marco

“…Most patients treated with US Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T cells eventually experience disease progression…”
Get more information

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort by Bowers, Jackson T., Anna, Jacob, Bair, Steven M., Annunzio, Kaitlin, Epperla, Narendranath, Pullukkara, Jerrin Joy, Gaballa, Sameh, Spinner, Michael A., Li, Shuning, Messmer, Marcus R., Nguyen, Joseph, Ayers, Emily C., Wagner, Charlotte B., Hu, Boyu, Di, Mengyang, Huntington, Scott F., Furqan, Fateeha, Shah, Nirav N., Chen, Christina, Ballard, Hatcher J., Hughes, Mitchell E., Chong, Elise A., Nasta, Sunita D., Barta, Stefan K., Landsburg, Daniel J., Svoboda, Jakub

“…•Most patients receiving BV plus AVD reported neuropathy, leading to BV discontinuation in 23%, a rate higher than that described in trials.•BV discontinuation…”
Get full text

Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma by Orellana-Noia, Victor M., Isaac, Krista, Malecek, Mary-Kate, Bartlett, Nancy L., Voorhees, Timothy J., Grover, Natalie S., Hwang, Steven R., Bennani, N. Nora, Hu, Rachel, Hill, Brian T., Mou, Eric, Advani, Ranjana H., Carter, Jordan, David, Kevin A., Ballard, Hatcher J., Svoboda, Jakub, Churnetski, Michael C., Magarelli, Gabriela, Feldman, Tatyana A., Cohen, Jonathon B., Evens, Andrew M., Portell, Craig A.

“…We performed a multicenter retrospective analysis across 10 US academic medical centers to evaluate treatment patterns and outcomes in patients age ≥60 years…”
Get full text

CAR T-Cell Immunotherapy in Minority Patients with Lymphoma by Ghilardi, Guido, Williamson, Staci, Pajarillo, Raymone, Paruzzo, Luca, Chen, Linhui, Grady, Connor, Doucette, Abigail, Nemecek, Eneida, Gabrielli, Giulia, Barta, Stefan K, Svoboda, Jakub, Chong, Elise A, Yelton, Rebecca, Nasta, Sunita D, Landsburg, Daniel J, Ugwuanyi, Ositadimma, Chen, Andy I, Schachter, Levanto, White, Griffin, Ballard, Hatcher J, Weber, Elizabeth, Curley, Cara, Porter, David L, Garfall, Alfred L, Hwang, Wei-Ting, Guerra, Carmen E, Maziarz, Richard T, Schuster, Stephen J, Ruella, Marco

“…Administration of anti-CD19 chimeric antigen receptor T-cell (CART19) immunotherapy for large B-cell lymphomas (LBCLs), a subset of non-Hodgkin lymphoma (NHL),…”
Get more information

COVID-19 pandemic experience in patients with Hodgkin lymphoma by Prischak, Sara E., Ballard, Hatcher J., Duca, Adam N., Gerson, James M., Landsburg, Daniel J, Barta, Stefan K., Svoboda, Jakub

“…e19534 Background: Patients (pts) with Hodgkin lymphoma (HL) may be at an increased risk from COVID-19-related complications due to immunosuppression and…”
Get full text

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma by Merryman, Reid W., Castagna, Luca, Giordano, Laura, Ho, Vincent T., Corradini, Paolo, Guidetti, Anna, Casadei, Beatrice, Bond, David A., Jaglowski, Samantha, Spinner, Michael A., Arai, Sally, Lowsky, Robert, Shah, Gunjan L., Perales, Miguel-Angel, De Colella, Jean Marc Schiano, Blaise, Didier, Herrera, Alex F., Shouse, Geoffrey, Spilleboudt, Chloe, Ansell, Stephen M., Nieto, Yago, Badar, Talha, Hamadani, Mehdi, Feldman, Tatyana A., Dahncke, Lori, Singh, Anurag K., McGuirk, Joseph P., Nishihori, Taiga, Chavez, Julio, Serritella, Anthony V., Kline, Justin, Mohty, Mohamad, Dulery, Remy, Stamatoulas, Aspasia, Houot, Roch, Manson, Guillaume, Moles-Moreau, Marie-Pierre, Orvain, Corentin, Bouabdallah, Kamal, Modi, Dipenkumar, Ramchandren, Radhakrishnan, Lekakis, Lazaros, Beitinjaneh, Amer, Frigault, Matthew J., Chen, Yi-Bin, Lynch, Ryan C., Smith, Stephen D., Rao, Uttam, Byrne, Michael, Romancik, Jason T., Cohen, Jonathon B., Nathan, Sunita, Phillips, Tycel, Joyce, Robin M., Rahimian, Maryam, Bashey, Asad, Ballard, Hatcher J., Svoboda, Jakub, Torri, Valter, Sollini, Martina, De Philippis, Chiara, Magagnoli, Massimo, Santoro, Armando, Armand, Philippe, Zinzani, Pier Luigi, Carlo-Stella, Carmelo

“…Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will…”
Get full text

Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors by Svoboda, Jakub, Ballard, Hatcher J, Ho, Carrie I, Hughes, Mitchell E., Chong, Elise A, Duca, Adam, Prischak, Sara, Dwivedy Nasta, Sunita, Ruella, Marco, Landsburg, Daniel J, Barta, Stefan K., Gerson, James N, Schuster, Stephen J.

“…Background: Patients (pts) with cancer are at higher risk for complications and mortality related to severe acute respiratory syndrome coronavirus 2…”
Get full text

Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study) by Svoboda, Jakub, Barta, Stefan K., Landsburg, Daniel J., Dwivedy Nasta, Sunita, Hwang, Wei-Ting, Delp, Grace, Amundsen, Brittany, Ballard, Hatcher J., Gerson, James N., Chong, Elise A., Hughes, Mitchell E., Emanuel, Steven A., Ruella, Marco, Schuster, Stephen J.

“…Background: Patients (pts) with relapsed/refractory classical Hodgkin lymphoma (r/r cHL) who fail or cannot tolerate both brentuximab vedotin (BV) and PD-1…”
Get full text

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas by Ghilardi, Guido, Chong, Elise A, Svoboda, Jakub, Wohlfarth, Philipp, Dwivedy Nasta, Sunita, Williamson, Staci, Landsburg, Daniel J, Gerson, James N, Barta, Stefan K., Pajarillo, Raymone, Myers, Jessie, Yelton, Rebecca, Ballard, Hatcher J., Gier, Shannon H, Victoriano, Danielle, Weber, Elizabeth, Napier, Ellen, Lacey, Simon F, Garfall, Alfred L., Porter, David L, Jaeger, Ulrich, Maziarz, Richard T., Ruella, Marco, Schuster, Stephen J

“…Background . Anti-CD19 chimeric antigen receptor T cells (CART19) are now a standard treatment for patients (pts) with relapsed/refractory (r/r) large B-cell…”
Get full text

Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel by Romancik, Jason T., Goyal, Subir, Gerson, James N, Ballard, Hatcher J, Sawalha, Yazeed, Bond, David A., Rogalski, Michael Joseph, Greenwell, Irl Brian, van Besien, Koen, Yamshon, Samuel, Karmali, Reem, Nizamuddin, Imran, Torka, Pallawi, Chow, Victor A., Shadman, Mazyar, Ghosh, Nilanjan, Moyo, Tamara K., Fenske, Timothy S., Rezazadeh, Alexandra, Grover, Natalie S, Maddocks, Kami J., Jacobson, Caron, Cohen, Jonathon B.

“…Background: Brexucabtagene autoleucel (brexu-cel) is the first CD19 chimeric antigen receptor T-cell (CAR T) therapy approved for use in patients (pts) with…”
Get full text

Concurrent Use of Novel Agents and Radiation Is Tolerated in Lymphoma Patients by Ho, Carrie I, Ballard, Hatcher J., Arscott, W. Tris, Hughes, Mitchell E., Doucette, Abigail, Landsburg, Daniel J., Dwivedy Nasta, Sunita, Gerson, James N., Maity, Amit, Schuster, Stephen J., Barta, Stefan K., Plastaras, John, Svoboda, Jakub

“…Introduction Novel agents such as ibrutinib, lenalidomide, and venetoclax are increasingly used in patients with relapsed/refractory lymphoma. A number of…”
Get full text

A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy by Dwivedy Nasta, Sunita, Hughes, Mitchell E., Namoglu, Esin C., Landsburg, Daniel J., Chong, Elise A., Barta, Stefan K., Frey, Noelle V., Gerson, James N., Maity, Amit, Plastaras, John, Porter, David L., Ruella, Marco, Svoboda, Jakub, Ballard, Hatcher J., Schuster, Stephen J.

“…Introduction: Implementation of cellular therapy has transformed the treatment paradigm for diffuse large B-cell lymphoma with sustained responses observed in…”
Get full text